Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/ refractory indolent lymphoma

Chan Yoon Cheah, Loretta J. Nastoupil, Sattva S. Neelapu, Sheryl G. Forbes, Yasuhiro Oki, Nathan H. Fowler

Research output: Contribution to journalLetter

70 Citations (Scopus)
Original languageEnglish
Pages (from-to)3357-3359
Number of pages3
JournalBlood
Volume125
Issue number21
DOIs
Publication statusPublished - 2015
Externally publishedYes

Cite this